Overview

Pars Plana Vitrectomy With Internal Limiting Membrane Peeling Versus Intravitreal Ziv-Aflibercept for Treatment-Naïve Diabetic Macular Edema

Status:
Recruiting

Trial end date:
2022-09-04

Target enrollment:

Participant gender:

Summary

Treatment-naïve subjects with center-involved diabetic macular edema undergoing pars plana vitrectomy with internal limiting membrane peeling will have similar visual outcomes but better anatomical outcomes compared to subjects undergoing intravitreal bevacizumab monotherapy at one year.

Phase:

Phase 3

Details

Lead Sponsor:

Rush Eye Associates

Collaborators:

Javier Castillo, MD
Pedro Gomez, MD
Ryan Rush, MD

Treatments:

Temazepam